



Codes ATC: J01DB01

Indication	Chronic obstructive pulmonary disease with acute exacerbation	Code ICD11: CA22.0
INN	Cefalexin	
Type de médicament	Chemical agent	
Groupes d'antibiotiques	A ACCESS	
Type de liste	Liste de base	
Formulations	Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid ; 250 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid: 250 mg (as monohydrate) ; 500 mg (as monohydrate)	
Historique des statuts LME	Ajouté pour la première fois en 2017 (TRS 1006) Modifié en 2021 (TRS 1035)	
Sexe	Tous	
Âge	Adolescents et adultes	
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique	
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite sur les brevets .	
Wikipédia	Cefalexin	
DrugBank	Cefalexin (Cephalexin)	

Recommandation du comité d'experts

The Expert Committee recommended inclusion of a new, higher strength formulation of cefalexin solid oral dosage form on the core list of the EML for the treatment of exacerbations of chronic obstructive pulmonary disease. The Committee noted that the proposed strength formulation is higher than those currently included on the Model List, and is appropriate and aligned to meet recommended doses for treatment of adults, with the advantages of a reduced pill burden.

Résumé des preuves

Most adult patients diagnosed with exacerbations of COPD can be successfully treated with cephalexin 500 mg every 12 hours for 5 days. The higher strength formulation will allow for a reduced pill burden to complete a course of treatment compared to the currently listed 250 mg strength formulation, and should facilitate adherence to treatment.

Recommandations de la LME : Chronic obstructive pulmonary disease with acute exacerbation

Premier choix

amoxicillin

amoxicillin + clavulanic acid

Second choix

cefalexin

doxycycline

